Kimberly-Clark's $40 Billion Bid for Kenvue Triggers Selloff, Creates Trading Opportunity

Kimberly-Clark's $40 billion bid for Tylenol maker Kenvue has triggered a selloff in the consumer health giant's shares, with the stock down nearly 16% in two days. The deal's value has decreased to around $18 per share, creating a potential arbitrage opportunity for traders. Strategist Brian Lombardi believes the deal's chances of closing are higher than the market has priced in, with the differential between the two stocks at around 65% to 70%.